Cornerstone Capital Management Holdings LLC. grew its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 9.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 14,483 shares of the biopharmaceutical company’s stock after buying an additional 1,294 shares during the period. Cornerstone Capital Management Holdings LLC.’s holdings in Regeneron Pharmaceuticals were worth $5,445,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. Steward Partners Investment Advisory LLC increased its stake in shares of Regeneron Pharmaceuticals by 495.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 307 shares during the period. Advisory Services Network LLC increased its stake in shares of Regeneron Pharmaceuticals by 147.0% during the fourth quarter. Advisory Services Network LLC now owns 447 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 266 shares during the period. Vident Investment Advisory LLC purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $200,000. Mackenzie Financial Corp purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $204,000. Finally, AE Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $206,000. 66.38% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms have recently issued reports on REGN. BidaskClub raised Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, January 26th. Royal Bank of Canada restated a “hold” rating and set a $430.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, December 14th. BTIG Research restated a “buy” rating and set a $520.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, November 22nd. Argus dropped their price target on Regeneron Pharmaceuticals from $540.00 to $470.00 and set a “buy” rating on the stock in a research report on Thursday, December 28th. Finally, Deutsche Bank initiated coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 12th. They set a “hold” rating and a $397.00 price target on the stock. Four analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $449.49.
Shares of REGN stock opened at $333.86 on Wednesday. The company has a quick ratio of 3.18, a current ratio of 3.82 and a debt-to-equity ratio of 0.11. Regeneron Pharmaceuticals Inc has a 1-year low of $313.53 and a 1-year high of $543.55. The company has a market capitalization of $36,972.04, a price-to-earnings ratio of 32.35, a price-to-earnings-growth ratio of 1.08 and a beta of 1.54.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.18 by $1.05. Regeneron Pharmaceuticals had a return on equity of 28.48% and a net margin of 20.41%. The business had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.50 billion. During the same period in the previous year, the company posted $3.04 earnings per share. The company’s revenue for the quarter was up 28.9% compared to the same quarter last year. sell-side analysts anticipate that Regeneron Pharmaceuticals Inc will post 19.2 EPS for the current fiscal year.
In other news, Director Joseph L. Goldstein sold 1,000 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $325.60, for a total transaction of $325,600.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Joseph L. Goldstein sold 2,000 shares of the company’s stock in a transaction on Monday, March 19th. The shares were sold at an average price of $350.02, for a total value of $700,040.00. Following the transaction, the director now directly owns 14,000 shares in the company, valued at $4,900,280. The disclosure for this sale can be found here. Insiders sold 5,000 shares of company stock worth $1,705,640 over the last three months. Corporate insiders own 10.80% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://ledgergazette.com/2018/03/21/regeneron-pharmaceuticals-inc-regn-shares-bought-by-cornerstone-capital-management-holdings-llc.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.